scholarly journals The role of B cell Activating Factor (BAFF) expression on pathogenesis of nasal polyp in chronic rhinosinusitis with nasal polyposis

2014 ◽  
Vol 52 (4) ◽  
pp. 390-396 ◽  
Author(s):  
Y.H. Yoon ◽  
J. Jin ◽  
K.R. Kwon ◽  
S.H. Kim ◽  
K.S. Rha ◽  
...  
2015 ◽  
Vol 2015 ◽  
pp. 1-9 ◽  
Author(s):  
Michal Rihacek ◽  
Julie Bienertova-Vasku ◽  
Dalibor Valik ◽  
Jaroslav Sterba ◽  
Katerina Pilatova ◽  
...  

B-cell activating factor (BAFF) is a cytokine and adipokine of the TNF ligand superfamily. The main biological function of BAFF in maintaining the maturation of B-cells to plasma cells has recently made it a target of the first FDA-approved selective BAFF antibody, belimumab, for the therapy of systemic lupus erythematosus. Concomitantly, the role of BAFF in cancer has been a subject of research since its discovery. Here we review BAFF as a biomarker of malignant disease activity and prognostic factor in B-cell derived malignancies such as multiple myeloma. Moreover, anti-BAFF therapy seems to be a promising approach in treatment of B-cell derived leukemias/lymphomas. In nonhematologic solid tumors, BAFF may contribute to cancer progression by mechanisms both dependent on and independent of BAFF’s proinflammatory role. We also describe ongoing research into the pathophysiological link between BAFF and cancer-related cachexia. BAFF has been shown to contribute to inflammation and insulin resistance which are known to worsen cancer cachexia syndrome. Taking all the above together, BAFF is emerging as a biomarker of several malignancies and a possible hallmark of cancer cachexia.


2000 ◽  
Vol 122 (2) ◽  
pp. 298-301 ◽  
Author(s):  
Yoke-Teen Pang ◽  
Orhan Eskici ◽  
Janet A. Wilson

Nasal polyposis is a common problem in otolaryngology. The cause remains unclear, and treatment with medication and surgery is often unsatisfactory. We present our controlled study, which suggests a strong association between food allergy and nasal polyposis. The study was conducted in 2 parts. A postal survey of 900 patients with nasal polyps showed 53 respondents (5.9%) had a known food allergy. In the prospective study, 80 nasal polyp patients and 36 control subjects completed intra-dermal tests for food allergy. Sixty-five nasal polyp patients (81%) and 4 control subjects (11%) had positive intradermal food test results. This is highly significant. We believe that food allergy may play a significant role in the pathogenesis of nasal polyposis and should be further studied.


2016 ◽  
Vol 137 (2) ◽  
pp. AB180
Author(s):  
Paul J. Maglione ◽  
Montserrat Cols ◽  
Emma Roellke ◽  
Lin Radigan ◽  
Charlotte Cunningham-Rundles

2015 ◽  
Vol 192 (6) ◽  
pp. 706-718 ◽  
Author(s):  
Leen J. M. Seys ◽  
Fien M. Verhamme ◽  
Anja Schinwald ◽  
Hamida Hammad ◽  
Danen Mootoosamy Cunoosamy ◽  
...  

2008 ◽  
Vol 121 (6) ◽  
pp. 1385-1392.e2 ◽  
Author(s):  
Atsushi Kato ◽  
Anju Peters ◽  
Lydia Suh ◽  
Roderick Carter ◽  
Kathleen E. Harris ◽  
...  

2018 ◽  
Vol 33 (2) ◽  
pp. 203-211 ◽  
Author(s):  
Alison G. Kartush ◽  
Jane K. Schumacher ◽  
Rachna Shah ◽  
Monica O. Patadia

Background Chronic rhinosinusitis with nasal polyposis is a complex inflammatory disorder, which is often recalcitrant to medical and surgical management. Recently, biologic agents have been studied as an adjunct treatment for this patient population. Objective The purpose of this study is to examine the role of biologic agents for chronic rhinosinusitis patients by reviewing literature and clinical trials. Methods A comprehensive review of literature and clinical trials—both recently completed and ongoing—was undertaken to examine up-to-date evidence of current biologic therapy and its role in chronic rhinosinusitis patients—including anti-IgE, anti-IL-4, anti-IL-5, anti-IL-13, and GATA-3 DNAzyme. Results Specific biologic agents discussed include omalizumab, reslizumab, mepolizumab, benralizumab, dupilumab, and Hgd40/SB010. Risks, side effects, and administration information are also reviewed. An algorithm for the use of biologics in patients with chronic rhinosinusitis with nasal polyposis is proposed. Conclusion These treatments have promising results and may prove to be an important adjunct for patients with recalcitrant sinus disease.


Sign in / Sign up

Export Citation Format

Share Document